Key information on Veltassa (patiromer), including efficacy and
tolerability data, how to prescribe and patients who
may benefit from treatment
Veltassa and RAASi
Discover the key clinical trials that show how Veltassa could enable RAASi therapy through the control of elevated K+
Veltassa tolerability
Find out more about Veltassa’s mode of action and tolerability profile
Once daily dosing
Understand how patients should prepare Veltassa and learn about the once-daily dosing regime
Transfer of care
Learn more about how patients can be initiated on Veltassa in secondary care and continued in primary care
Chronic Patient case studies
Review two patient case studies where persistent elevated K+ is preventing optimal RAAS inhibition therapy and decide whether Veltassa could help
Acute patient case study
Review a patient with acute hyperkalaemia and understand where Veltassa could fit within their treatment
VELTASSA IN THE ACUTE SETTING
See how daily doses of Veltassa as a monotherapy provided potassium control to patients in a cohort study of hyperkalaemia in the acute care setting.
RAAS, renin-angiotensin-aldosterone system ; RAASi, renin-angiotensin-aldosterone system inhibition.